Dravet syndrome is a rare genetic epileptic encephalopathy that begins during the first year of life in an otherwise healthy infant. According to the National Center for Advancing Translational Sciences, in 15% to 25% cases of the Dravet syndrome, a family history of epilepsy or febrile seizures exists. It is also reported that 85% cases of Dravet syndrome originated due to a mutation in the SCN1A gene.
It is noted that development of new drugs and therapies, and rising R&D expenditure are propelling the growth of the market. In recent years, Dravet syndrome has gained significant attention due to the upcoming drugs for its treatment. For instance, on February 06, 2018, Zogenix, Inc. received breakthrough therapy designation from FDA for its product, ZX008. The drug is specialized for the treatment of Dravet syndrome and its related complications.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5509
Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the global Dravet syndrome market.
Despite these drivers, there are some issues associated with Dravet syndrome market. The side effects of drugs and other therapeutic agents, lack of awareness in the developing countries, and poor healthcare system in low and middle-income countries, may hinder the growth of the market.
It is estimated that the Dravet syndrome market is expected to grow at a CAGR of 8.5% during the forecast period of 2017-2023.
Intended Audience:
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Government Research Institute
- Academic Institutes and Universities
Key Players:
Some of key the players in the global dravet syndrome market are Biocodex, Biscayne Neurotherapeutics, Cyberonics, Inc., Epygenix Therapeutics, Inc., GW Pharmaceuticals, plc, INSYS THERAPEUTICS, INC., OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics, Sage Therapeutics, Takeda Pharmaceutical Company Limited, Thermo Fisher Life Technologies, Xenon Pharmaceuticals, Zogenix, Inc, and others.
Segmentation:
The global Dravet syndrome market is segmented on the basis of the type of seizures, diagnosis, treatment & management, and end-user.
On the basis of the type of seizures, the market is classified as myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic clonic seizures, photosensitive seizures, and others.
On the basis of the diagnosis, the market is classified as magnetic resonance imaging (MRI), electroencephalography (EEG), SCN1A testing, and others.
On the basis of the treatment & management, the market is classified as seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others. The seizure medications segment is further classified into clobazam, stiripentol, sodium valproate, and others.
On the basis of the end-user, the market is segmented into pharmaceutical companies, hospitals, diagnostic laboratories, academic and research institutes, and others.
Browse More Details of the Report @
@ https://www.marketresearchfuture.com/reports/dravet-syndrome-market-5509
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: [email protected]
Dravet syndrome is a rare epileptic disorder affecting infants.
It is also known as severe myoclonic epilepsy of infancy (SMEI).
According to the National Center for Advancing Sciences, nearly 15-25% of the cases of the disorder have a family history of febrile seizures or epilepsy.
The global Dravet syndrome market report by Market Research Future (MRFR) has been compiled by a blend of primary and secondary research.The global Dravet syndrome market is expected to magnify its valuation at 8.5% CAGR from 2017 to 2023 (forecast period).
Other major drivers include reimbursement policies offering coverage of rare diseases, improvement in regulatory framework, and unmet medical needs of patients.Adverse effects of the drugs, low awareness of the disease, and low planning of healthcare in low- and mid-income countries are some of the restraints which can impede market growth.Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/5509 Competition OutlookOvid Therapeutics, OPKO Health Inc., Zogenix, Inc, Biocodex, Biscayne Neurotherapeutics, Takeda Pharmaceutical Company Limited, Sage Therapeutics, Xenon Pharmaceuticals, INSYS THERAPEUTICS, INC., Epygenix Therapeutics, Inc., Thermo Fisher Life Technologies, PTC Therapeutics, GW Pharmaceuticals, plc, and Cyberonics, Inc. are the biggest players in the global Dravet syndrome market.SegmentationThe global Dravet syndrome market is segmented on the basis of the type of seizures, diagnosis, treatment & management, and end-user.On the basis of the Type of Seizures, it is classified as myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic clonic seizures, photosensitive seizures, and others.On the basis of the Diagnosis, it is segmented as magnetic resonance imaging (MRI), electroencephalography (EEG), SCN1A testing, and others.On the basis of the Treatment and Management, the market is segmented into seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others.
The seizure medications segment is further classified into clobazam, stiripentol, sodium valproate, and others.On the basis of the End-user, the global Dravet syndrome market is segmented into pharmaceutical companies, hospitals, diagnostic laboratories, academic and research institutes, and others.Regional AnalysisThe Americas, Europe, the Middle East & Africa (MEA), and Asia Pacific (APAC) are the major segments according to region.The Americas are presumed to dominate the global market till 2023 due to the increased healthcare budget by governments in the region for the welfare of their patients.
So far, more than 100 different cannabinoids have been identified, and there is a growing body of evidence supporting the clinical benefits of this class of compounds in treating the symptoms of a wide variety of chronic health conditions Roots Analysis is pleased to announce the publication of its recent study, titled, “Endocannabinoid System Targeted Therapeutics Market, 2020-2030.“ The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade.
The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
In addition to other elements, the study includes:A detailed assessment of the current market landscape of drug developers engaged in the development of endocannabinoid system targeted therapeutics.Detailed profiles of developers of endocannabinoid system targeted therapeutics(shortlisted on the basis of the number of development programs).An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted therapeuticsAn analysis of the partnerships that have been established in this domain, in the recent past.A detailed analysis of the various mergers and acquisitions that have taken place in this domain, between 2016-2020An insightful chessboard analysis highlighting the most popular drug development strategies / paths adopted by various drug developers in the domain of endocannabinoid system targeted therapeutics.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Target Disease IndicationCancerGenetic DisordersNeurological IndicationsOthersRoute of AdministrationOralInhalationKey GeographiesNorth AmericaEuropeAsia-Pacific and the Rest of the World Key companies covered in the reportGW PharmaceuticalsCorbus PharmaceuticalsTilrayTetra Bio-PharmaBotanix PharmaceuticalsKalytera TherapeuticsTherapix BiosciencesEcho PharmaceuticalsAvicannaGB Sciences For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html Other Recent Offerings Neoantigen Targeted Therapies Market, 2019-2030Blood-Brain Barrier (BBB) Market (2nd Edition), 2020-2030: Focus on Non-Invasive Drug Delivery Technology Platforms and TherapeuticsBispecific Antibody Therapeutics Market (4th Edition), 2019-2030Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030 Contact: Gaurav Chaudhary +1 (415) 800 3415+44 (122) 391 1091 [email protected] About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.
The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]
The latest trending report Global Infantile Spasms Therapeutics Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 offered by DecisionDatabases.com is an informative study covering the market with detailed analysis.
The report will assist reader with better understanding and decision making.The Infantile Spasms Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.This report also researches and evaluates the impact of Covid-19 outbreak on the Infantile Spasms Therapeutics industry, involving potential opportunity and challenges, drivers and risks.
We present the impact assessment of Covid-19 effects on Infantile Spasms Therapeutics and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.
).Final Report will cover the impact of COVID-19 on this industry.Browse the complete report and table of contents @ https://www.decisiondatabases.com/ip/29733-infantile-spasms-therapeutics-market-analysis-reportThe major players covered in Infantile Spasms Therapeutics are:MallinckrodtRetrophinOrphelia PharmaH.
LundbeckAnavex Life SciencesInsys TherapeuticsCatalyst PharmaceuticalsValerion TherapeuticsGW PharmaceuticalsBy Type, Infantile Spasms Therapeutics market has been segmented into:OralInjectionBy Application, Infantile Spasms Therapeutics has been segmented into:HospitalClinicThe report offers in-depth assessment of the growth and other aspects of the Infantile Spasms Therapeutics market in important countries (regions), including:North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)South America (Brazil, Argentina, Colombia)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)Download Free Sample Report of Global Infantile Spasms Therapeutics Market @ https://www.decisiondatabases.com/contact/download-sample-29733There are 14 Chapters to deeply display the global Infantile Spasms Therapeutics market.1 Infantile Spasms Therapeutics Market Overview2 Company Profiles3 Global Infantile Spasms Therapeutics Market Competition, by Players4 Global Infantile Spasms Therapeutics Market Size by Regions5 North America Infantile Spasms Therapeutics Revenue by Countries6 Europe Infantile Spasms Therapeutics Revenue by Countries7 Asia-Pacific Infantile Spasms Therapeutics Revenue by Countries8 South America Infantile Spasms Therapeutics Revenue by Countries9 Middle East and Africa Revenue Infantile Spasms Therapeutics by Countries10 Global Infantile Spasms Therapeutics Market Segment by Type11 Global Infantile Spasms Therapeutics Market Segment by Application12 Global Infantile Spasms Therapeutics Market Size Forecast (2021-2025)13 Research Findings and Conclusion14 AppendixPurchase the complete Global Infantile Spasms Therapeutics Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-29733All Therapeutics Related Reports by DecisionDatabases.com @ https://goo.gl/pzpPL3About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.
DecisionDatabases.com is proficient in providing syndicated research report, customized research reports, company profiles and industry databases across multiple domains.Our expert research analysts have been trained to map client’s research requirements to the correct research resource leading to a distinctive edge over its competitors.
Market Research Future (MRFR) reports that Security Testing market is likely to touch an approx.
The global market was valued at USD 3.67 billion in 2017, according to the report.The global security testing market is estimated to grow at a significant rate during the forecast period.
The major features of security testing are protection and secure access to data is mentioned in this report.
These features are suitable for both web-based and desktop-based applications.
Factors contributing to the growth of the security testing market are increasing demands for protecting customer data and web and mobile applications, increasing adoption of cloud-based security solutions, increasing the number of cyberattacks, and the need to strengthen security..Factors contributing to the growth of security testing market:The Security Testing Market has encountered noteworthy growth over the recent years and is anticipated to grow tremendously over the assessment period.
One of the major factors responsible for the growth of security testing market is the deployment of data centers across industries due to which enterprises are realizing the need to implement security testing solutions.
Market Research Future published a research report on “WiFi Booster Global Market Research Report- Forecast 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.Market Scenario:The WiFi booster market is growing rapidly across the world.
The increasing number of smart devices are developed which is propelling the demand of Wifi booster market is due to increasing need of strong network connectivity is also be required.
These smart devices are compatible with latest internet connectivity are widely used among users and is estimated to gain growth in the forthcoming years.
These Wi-Fi booster are generally user friendly and cost effective.Get Free Sample Report @ https://www.marketresearchfuture.com/sample_request/4037With the increasing demand of smart devices among users including smart watches, smartphones, tablets, smart glasses and other personal electronics which is boosting the market growth to the large extent.
The Wi-Fi booster can help to fulfil the need of the Internet of things.According to Market Research Future analysis, global WiFi Booster Market has been valued at USD ~ 3,155.25 million by the end of forecast period with ~18%% of CAGR during forecast period 2017 to 2023.Key PlayersThe prominent players in the global Wi-Fi booster market are – Netgear, Inc. (U.S.), Ruckus Wireless, Inc. (U.S.), Juniper Networks (U.S.), Motorola Solutions, Inc. (U.S.), Cisco Systems, Inc. (U.S.), Alcatel-Lucent S.A. (France), Aruba Networks (U.S.), Ericsson (Sweden), D-Link Corporation (Taiwan) and TP-Link (China), among others.Segments:The global Wi-Fi booster market is bifurcated on the basis of type, services, solution, and region.
The type is segmented into indoor, and outdoor.
Various activities including earthmoving, material handling, transporting materials, etc.
The global heavy construction equipment industry growth is directly related to the worldwide infrastructural development activities.
Addition of new technologies to the existing systems has been an ongoing trend within the market.
Some of the major players operating within heavy construction equipment market arena include Volvo Construction Equipment, Hitachi Construction Machinery Co., Ltd., Caterpillar Inc., J.C. Bamford Excavators Limited (JCB), Doosan Heavy Industries & Construction, Komatsu Ltd.,, and others.Huge investments in infrastructural projects in BRIC countries have spurred the demand for heavy construction equipment for commercial and residential purpose.
The construction companies are now focusing their attention to India for business.
The equipment developed includes wheel loaders, backhoe loaders, and excavators.
